Healios K.K. (HLOSF)
HLOSF Stock Price Chart
Explore Healios K.K. interactive price chart. Choose custom timeframes to analyze HLOSF price movements and trends.
HLOSF Company Profile
Discover essential business fundamentals and corporate details for Healios K.K. (HLOSF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Nov 2020
Employees
65.00
Website
https://www.healios.co.jpCEO
Tadahisa S. Kagimoto
Description
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
HLOSF Financial Timeline
Browse a chronological timeline of Healios K.K. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.05 by -199.09%, while revenue for the quarter reached $152.66K , missing expectations by -94.66%.
Earnings released on 13 May 2025
EPS came in at -$0.18 surpassing the estimated -$0.19 by +8.02%, while revenue for the quarter reached $253.31K , missing expectations by -89.73%.
Earnings released on 12 Feb 2025
EPS came in at $0.02 surpassing the estimated -$0.07 by +127.69%, while revenue for the quarter reached $114.48K , beating expectations by +620.00%.
Earnings released on 13 Nov 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -46.17%, while revenue for the quarter reached $236.54K , beating expectations by +1.26K%.
Earnings released on 13 Aug 2024
EPS came in at -$0.04 falling short of the estimated -$0.03 by -20.62%, while revenue for the quarter reached $3.10M , missing expectations by -13.57%.
Earnings released on 13 May 2024
EPS came in at -$0.19 falling short of the estimated -$0.05 by -249.56%, while revenue for the quarter reached $65.92K , missing expectations by -95.44%.
Earnings released on 14 Feb 2024
EPS came in at -$0.17 falling short of the estimated -$0.10 by -60.10%, while revenue for the quarter reached $50.04K , beating expectations by +106.19%.
Earnings released on 30 Sept 2023
EPS came in at -$0.07 surpassing the estimated -$0.09 by +26.70%, while revenue for the quarter reached $46.84K .
Earnings released on 30 Jun 2023
EPS came in at -$0.07 surpassing the estimated -$0.11 by +35.04%, while revenue for the quarter reached $691.95K , beating expectations by +1.53K%.
Earnings released on 31 Mar 2023
EPS came in at -$0.09 surpassing the estimated -$0.10 by +13.47%, while revenue for the quarter reached $52.83K , beating expectations by +100.53%.
Earnings released on 14 Feb 2023
EPS came in at -$19.54 falling short of the estimated $4.04 by -583.66%, while revenue for the quarter reached $462.56K , beating expectations by +302.24%.
Earnings released on 14 Nov 2022
EPS came in at -$12.30 surpassing the estimated -$12.42 by +0.97%, while revenue for the quarter reached $55.33K .
Earnings released on 9 Aug 2022
EPS came in at -$32.64 falling short of the estimated -$1.54 by -2.02K%, while revenue for the quarter reached $80.93K , beating expectations by +2.10K%.
Earnings released on 10 May 2022
EPS came in at -$26.48 falling short of the estimated -$10.97 by -141.39%, while revenue for the quarter reached $89.96K , beating expectations by +119.01%.
Earnings released on 14 Feb 2022
EPS came in at -$22.04 surpassing the estimated -$49.21 by +55.21%, while revenue for the quarter reached $95.64K , beating expectations by +10.10%.
Earnings released on 12 Nov 2021
EPS came in at -$34.78 falling short of the estimated -$28.93 by -20.22%, while revenue for the quarter reached $98.75K .
Earnings released on 10 Aug 2021
EPS came in at -$16.68 surpassing the estimated -$41.63 by +59.93%, while revenue for the quarter reached $89.98K .
Earnings released on 14 May 2021
EPS came in at -$19.92 surpassing the estimated -$25.94 by +23.21%, while revenue for the quarter reached $81.42K .
Earnings released on 12 Feb 2021
EPS came in at -$29.02 , while revenue for the quarter reached $58.07K .
Earnings released on 13 Nov 2020
EPS came in at -$27.35 , while revenue for the quarter reached $66.31K .
HLOSF Stock Performance
Access detailed HLOSF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.